- Investing.com
Metrics to compare | PEPG | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPEPGPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.1x | −7.5x | −0.4x | |
PEG Ratio | −0.03 | −0.03 | 0.00 | |
Price/Book | 1.2x | 3.5x | 2.6x | |
Price / LTM Sales | - | 64.1x | 3.0x | |
Upside (Analyst Target) | - | 62.4% | 51.9% | |
Fair Value Upside | Unlock | −5.2% | 9.1% | Unlock |
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.